tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2017 Oct 11. pii: CVI.00248-17. doi: 10.1128/CVI.00248-17. [Epub ahead of print]
[h=1]Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.[/h] Changsom D[SUP]1[/SUP], Jiang L[SUP]1[/SUP], Lerdsamran H[SUP]2[/SUP], Iamsirithaworn S[SUP]3[/SUP], Kitphati R[SUP]3[/SUP], Pooruk P[SUP]4[/SUP], Auewarakul P[SUP]1[/SUP], Puthavathana P[SUP]5,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The kinetics, longevity and breadth of antibodies to influenza neuraminidase (NA) in archival, sequential serum/plasma samples from influenza A virus (IAV) H5N1 survivors, and from patients infected with the 2009 pandemic IAV (H1N1) virus were determined using an enzyme linked lectin based assay. The reverse genetics-derived H4N1 viruses harboring an hemagglutinin (HA) segment from A/duck/Shan Tou/461/2000 (H4N9) and an NA segment derived from either IAV H5N1 clade 1, IAV H5N1 clade 2.3.4, the 2009 pandemic IAV (H1N1) (H1Npdm) or A/Puerto Rico/8/1934 (H1N1) virus were used as the test antigens. These sera/plasma samples were also investigated by microneutralization (MN) and/or hemagglutination-inhibition (HI) assays. Neuraminidase-inhibiting (NI) antibodies against N1 NA of both homologous and heterologous viruses were observed in H5N1 survivors and H1N1pdm patients. H5N1 survivors who never exposed to H1N1pdm virus developed NI antibodies to H1N1pdm NA. Seroconversion of NI antibodies was observed in 65% of the H1N1pdm patients at day 7 after disease onset, but an increase in titer was not observed in late serum samples. On the other hand, an increase in seroconversion rate with HI assay was observed in the follow-up series of sera obtained on days 7, 14, 28 and 90 after infection. The study also showed that NI antibodies are broadly reactive, while MN and HI antibodies are more strain specific.
Copyright ? 2017 American Society for Microbiology.
PMID: 29021304 DOI: 10.1128/CVI.00248-17
[h=1]Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.[/h] Changsom D[SUP]1[/SUP], Jiang L[SUP]1[/SUP], Lerdsamran H[SUP]2[/SUP], Iamsirithaworn S[SUP]3[/SUP], Kitphati R[SUP]3[/SUP], Pooruk P[SUP]4[/SUP], Auewarakul P[SUP]1[/SUP], Puthavathana P[SUP]5,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The kinetics, longevity and breadth of antibodies to influenza neuraminidase (NA) in archival, sequential serum/plasma samples from influenza A virus (IAV) H5N1 survivors, and from patients infected with the 2009 pandemic IAV (H1N1) virus were determined using an enzyme linked lectin based assay. The reverse genetics-derived H4N1 viruses harboring an hemagglutinin (HA) segment from A/duck/Shan Tou/461/2000 (H4N9) and an NA segment derived from either IAV H5N1 clade 1, IAV H5N1 clade 2.3.4, the 2009 pandemic IAV (H1N1) (H1Npdm) or A/Puerto Rico/8/1934 (H1N1) virus were used as the test antigens. These sera/plasma samples were also investigated by microneutralization (MN) and/or hemagglutination-inhibition (HI) assays. Neuraminidase-inhibiting (NI) antibodies against N1 NA of both homologous and heterologous viruses were observed in H5N1 survivors and H1N1pdm patients. H5N1 survivors who never exposed to H1N1pdm virus developed NI antibodies to H1N1pdm NA. Seroconversion of NI antibodies was observed in 65% of the H1N1pdm patients at day 7 after disease onset, but an increase in titer was not observed in late serum samples. On the other hand, an increase in seroconversion rate with HI assay was observed in the follow-up series of sera obtained on days 7, 14, 28 and 90 after infection. The study also showed that NI antibodies are broadly reactive, while MN and HI antibodies are more strain specific.
Copyright ? 2017 American Society for Microbiology.
PMID: 29021304 DOI: 10.1128/CVI.00248-17